NCT03270176View on ClinicalTrials.gov

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

March 22, 2022

Study Completion Date

March 22, 2022

Conditions
Carcinoma, Non-Small-Cell LungNeoplasms
Interventions
DRUG

Debio 1143

Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.

DRUG

Avelumab

Avelumab 10 mg/kg intravenous infusion every 2 weeks.

Trial Locations (9)

200347

Centrul de Oncologie, S.C. Centrul de Oncologie Sf. Nectarie S.R.L, Oncologie Medicala, Craiova

400015

"Institutul Oncologic Prof. Dr. Ion Chiricuţă Cluj Napoca", Cluj-Napoca

T6G 1Z2

Cross Cancer Center Dept Medicine, Edmonton

V5Z 4E6

British Columbia Cancer Agency, Vancouver

L8V 5C2

Juravinski Cancer Centre, Hamilton

K1H 8L6

The Ottawa Hospital Cancer Centre (TOHCC), Ottawa

90-320

Instytut Medyczny Santa Familia Sp. z o. o., Lodz

60-693

Med-Polonia Sp. z o.o., Ulica Obornicka, Poznan

87-100

Wojewódzki Szpital Zespolony im. Ludwika Rydygiera, Torun

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY